Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Johnson & Johnson may have pulled off one of the most efficient cancer-drug deals in modern pharma, but the story is becoming more complicated as rivals rush into the same field.</li><li>In 2017, J&J secured rights to Legend Biotech’s Carvykti for just $350 million upfront, a fraction of the $11 billion Gilead paid for Kite Pharma to enter CAR-T therapy.</li><li>That early bet has turned into a major commercial win: Carvykti became the world’s bestselling CAR-T therapy in 2025, with nearly $2 billion in sales, and J&J’s latest earnings call showed roughly $600 million in Q1 2026 sales, up 57.4% operationally.</li></ul>

Johnson & Johnson may have pulled off one of the most efficient cancer-drug deals in modern pharma, but the story is becoming more complicated as rivals rush into the same field.In 2017, J&J secured rights to Legend Biotech’s Carvykti for just $350 million upfront, a fraction of the $11 billion Gilead paid for Kite Pharma to enter CAR-T therapy.That early bet has turned into a major commercial win: Carvykti became the world’s bestselling CAR-T therapy in 2025, with nearly $2 billion in sales, and J&J’s latest earnings call showed roughly $600 million in Q1 2026 sales, up 57.4% operationally.

J&J’s $350 Million Cancer Bet Is Becoming A Pharma Goldmine!

<ul><li>Johnson & Johnson (JNJ) reported strong financial results for the fourth quarter and full year of 2025, emphasizing its continued growth trajectory in both the Innovative Medicine and MedTech segments.</li><li>The company delivered 5.3% operational sales growth for the full year, reaching $94.2 billion, despite facing headwinds from the loss of exclusivity (LOE) of STELARA.</li><li>This performance underscores Johnson & Johnson's robust portfolio, which includes 28 platforms or products generating at least $1 billion in annual revenues, ensuring a diversified and resilient growth model.</li></ul>

Johnson & Johnson (JNJ) reported strong financial results for the fourth quarter and full year of 2025, emphasizing its continued growth trajectory in both the Innovative Medicine and MedTech segments.The company delivered 5.3% operational sales growth for the full year, reaching $94.2 billion, despite facing headwinds from the loss of exclusivity (LOE) of STELARA.This performance underscores Johnson & Johnson's robust portfolio, which includes 28 platforms or products generating at least $1 billion in annual revenues, ensuring a diversified and resilient growth model.

Johnson & Johnson’s Innovative Medicine Pipeline Is Stacked—The Oncology Expansion That Could Surprise Investors!

<ul><li>Johnson & Johnson is preparing for what could become one of the largest medtech transactions in recent years: a potential $20+ billion sale of its DePuy Synthes orthopedics unit.</li><li>According to recent reports, the company is assembling financial materials and engaging with prospective buyers, including large private equity firms that may team up to pursue the asset.</li><li>DePuy Synthes generated approximately $9.3 billion in annual sales and, if separated, would become the largest standalone orthopedics company globally.</li></ul>

Johnson & Johnson is preparing for what could become one of the largest medtech transactions in recent years: a potential $20+ billion sale of its DePuy Synthes orthopedics unit.According to recent reports, the company is assembling financial materials and engaging with prospective buyers, including large private equity firms that may team up to pursue the asset.DePuy Synthes generated approximately $9.3 billion in annual sales and, if separated, would become the largest standalone orthopedics company globally.

J&J’s $20B Orthopedics Exit? The DePuy Synthes Sale That Could Reshape MedTech Capital Allocation!

<ul><li>Johnson & Johnson has become the latest pharmaceutical heavyweight to voluntarily align with the Trump administration’s drug pricing agenda, striking a deal that aims to significantly lower prices for select medications in the United States.</li><li>The agreement includes a commitment to offer “internationally comparable” pricing and encompasses Medicaid drug sales, directly addressing mounting political pressure over U.S. pharmaceutical costs.</li><li>As part of the deal, J&J will also participate in the administration's new TrumpRx.gov initiative—a public platform designed to give American patients access to discounted medications.</li></ul>

Johnson & Johnson has become the latest pharmaceutical heavyweight to voluntarily align with the Trump administration’s drug pricing agenda, striking a deal that aims to significantly lower prices for select medications in the United States.The agreement includes a commitment to offer “internationally comparable” pricing and encompasses Medicaid drug sales, directly addressing mounting political pressure over U.S. pharmaceutical costs.As part of the deal, J&J will also participate in the administration's new TrumpRx.gov initiative—a public platform designed to give American patients access to discounted medications.

Johnson & Johnson Joins TrumpRx.gov—The Shocking Details Inside!

<ul><li>Johnson & Johnson's first quarter 2025 results present a multifaceted picture of a robust yet intricately challenged healthcare company.</li><li>The operational sales growth stood at 4.2%, even as they faced significant pressure due to the loss of exclusivity for STELARA, a multibillion-dollar pharmaceutical product.</li><li>Despite an 810 basis point headwind from STELARA, the Innovative Medicine sector showed resilience with an equal 4.2% growth, supported by strength in other key pharmaceuticals such as DARZALEX, which achieved a notable growth of over 20%.</li></ul>

Johnson & Johnson's first quarter 2025 results present a multifaceted picture of a robust yet intricately challenged healthcare company.The operational sales growth stood at 4.2%, even as they faced significant pressure due to the loss of exclusivity for STELARA, a multibillion-dollar pharmaceutical product.Despite an 810 basis point headwind from STELARA, the Innovative Medicine sector showed resilience with an equal 4.2% growth, supported by strength in other key pharmaceuticals such as DARZALEX, which achieved a notable growth of over 20%.

Johnson & Johnson Buys Halda: The Cancer Deal Wall Street Didn’t See Coming!

United States

Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Johnson & Johnson (JNJ UN)

J&J’s $350 Million Cancer Bet Is Becoming A Pharma Goldmine!

Johnson & Johnson may have pulled off one of the most efficient cancer-drug deals in modern pharma, but the story is becoming more complicated...

Baptista Research

Johnson & Johnson’s Innovative Medicine Pipeline Is Stacked—The Oncology Expansion That Could Surprise Investors!

Johnson & Johnson (JNJ) reported strong financial results for the fourth quarter and full year of 2025, emphasizing its continued growth...

Baptista Research

J&J’s $20B Orthopedics Exit? The DePuy Synthes Sale That Could Reshape MedTech Capital Allocation!

Johnson & Johnson is preparing for what could become one of the largest medtech transactions in recent years: a potential $20+ billion sale of...

Baptista Research

Johnson & Johnson Joins TrumpRx.gov—The Shocking Details Inside!

Johnson & Johnson has become the latest pharmaceutical heavyweight to voluntarily align with the Trump administration’s drug pricing agenda,...

Baptista Research

Johnson & Johnson Buys Halda: The Cancer Deal Wall Street Didn’t See Coming!

Johnson & Johnson's first quarter 2025 results present a multifaceted picture of a robust yet intricately challenged healthcare company. The...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)